European Guidelines (S3) on Diagnosis & Management of Mucous Membrane Pemphigoid, Initiated by the EADV- Part I |
Journal Updates
eMediNexus Coverage from: 
European Guidelines (S3) on Diagnosis & Management of Mucous Membrane Pemphigoid, Initiated by the EADV- Part I
eMediNexus,  13 May 2022
Coronavirus Live Count Map India

remove_red_eye 646 Views
COVID-19 Vaccine Updates


#Dermatology

0 Read Comments                

The Task Force for Autoimmune Blistering Diseases of the EADV has recently framed an S3 consensus‐based guideline illustrating mucous membrane pemphigoid (MMP). 

The summary of Part I is as follows:

MMP symbolizes a cluster of autoimmune skin and mucous membrane blistering diseases, determined by a chronic duration and by engagement of the mucous membranes.

Mono‐ or multisite involvement may be seen in MMP patients, with their autoantibodies predominantly produced against BP180, BP230, laminin 332 and type VII collagen, constituents of junctional adhesion complexes facilitating epithelial-stromal attachment in stratified epithelia. 

Various disease assessment scores can be used like-

  • The Mucous Membrane Pemphigoid Disease Area Index (MMPDAI) 
  • The Autoimmune Bullous Skin disorder Intensity Score (ABSIS) 
  • The ‘Cicatrising Conjunctivitis Assessment Tool’ 
  • The Oral Disease Severity Score (ODSS). 

Quality of life can be assessed via patient‐reported outcome measurements (PROMs), like the Dermatology Life Quality Index (DLQI), Autoimmune Bullous Disease Quality of Life (ABQOL) and Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL). This will not only help to assess the effectiveness of therapeutic interventions but will also monitor the disease course.

To comment on this article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now